NCI SBIR grant for Personalized Cancer-on-a-Chip
MIMETAS wins NCI SBIR grant for Personalized Cancer-on-a-Chip models with University of Texas Health Science Center and MD Anderson
MIMETAS, the market leader in Organ-on-a-chip products, announced that the National Cancer Institute recently awarded them a phase 1 SBIR grant totally $300,000 to develop personalized prostate cancer-on-a-chip models that can more accurately reproduce the tumor micro-environment. MIMETAS has built a consortium with the University of Texas Health Science Center (UTHSC) and MD Anderson to build the next generation platform for cancer drug screening and personal therapy prediction.
Accurate prediction of cancer drug efficacy is a major problem in oncology therapeutics development and therapy selection. In the project the collaborators will gain access to a library of patient derived xenograft (PDX) and primary tumor samples to create a racially diverse and representative population of prostate cancer models with unprecedented predictivity and usability.
"We're very excited to be working with Dan and Nora's team on this project", says Dr. Anthony Saleh of MIMETAS, Principle Investigator for the project. "Prof. Harrington and Navone are leaders in developing in vitro 3D cancer cultures. "We are extremely impressed with the MIMETAS OrganoPlate platform", commented Prof. Harrington. "It enables perfused 3D co-culture with a vascular, tumor stroma, and immune compartments. The ability to scale models into HTS screening is quite unique in the Organ-on-a-Chip space".
About the NCI SBIR Program
The National Cancer Institute (NCI) leads, conducts, and supports cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Small businesses are a national resource for technological innovation and a mainstay of the economy. The SBIR & STTR Programs were created by Congress to strengthen the role of small, innovative companies in federally supported research and development.
About University of Texas Health Science Center Department of Diagnostic and Biomedical Sciences
The School of Dentistry's location in the Texas Medical Center provides unparalleled opportunities for collaboration with local, national and international research partners. The integration with the Center for Clinical and Translational Sciences (CCTS) provides exceptional resources for planning clinical trials, biostatistics, bioethics, epidemiology, and core facilities for various types of biological assays. The school's state-of-the-art biomedical research laboratories are located in the UT Behavioral & Biomedical Sciences Building, which is connected to the School of Dentistry.
About MD Anderson Department of Genitourinary Medical Oncology
Our clinical care is based on research into the biology of genitourinary tumors. With a clearer understanding of the biologic behavior of genes, molecules, and cells that are responsible for the formation and growth of these tumors, we have been able to develop treatments tailored to the individual patient. The Department of Genitourinary Medical Oncology is at the leading edge of research to identify important biologic markers to help us determine which patients are at greatest risk of advanced disease and metastasis. These powerful tools combined with the use of innovative therapeutic agents will increase survival and promote a better quality of life for patients with genitourinary cancers. The Department has created an interactive environment in which ideas are freely exchanged among basic science, translational, and clinical investigators in the Genitourinary Cancer Center, the David H. Koch Center for Applied Research of Genitourinary Cancers, throughout the institution, and around the world.